Lenacapavir

For the prevention of HIV in cisgender women, there are variations in the uptake, adherence, and durability of preexposure prophylaxis. This study tested the effectiveness of subcutaneous lenacapavir and daily oral emtricitabine–tenofovir alafenamide (F/TAF) versus daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) in preventing HIV among adolescent girls and young women in South Africa and Uganda.

This is a case report regarding a hemodialysis MDR HIV-infected patient who switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and presented no clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising regarding safety and efficacy, even in patients with

The purpose of this article is to review the pharmacology, efficacy, and safety of the capsid inhibitor lenacapavir for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection. A review of the literature was performed by searching PubMed/MEDLINE for all relevant articles published between February 2021 and March 2023 using the keywords “lenacapavir,”

Pre-exposure prophylaxis (PrEP) using long-acting antiretroviral medications is a promising new HIV preventive method to daily oral regimens. A first-in-class long-acting capsid inhibitor called lenacapavir (LEN) has been licensed for the treatment of HIV-1 infection. In this study, the authors used a single high-dose simian-human immunodeficiency virus (SHIV) rectal challenge macaque 39 paradigms to evaluate

Incorporating LA ARVs and bNAbs into regimens has proven to be a challenging task. For the dosage schedules of the two medicines to work together, identical half-lives are required. Additionally, bNAb susceptibility testing is required to ensure that the bNAb is active in order to protect against the possibility of developing resistance to the LA

A literature search was performed using PubMed and Google Scholar (through March 2023) with the search term LEN and GS-6207 to review the efficacy, safety, and role of lenacapavir (LEN) in treating HIV-1 infection.

The researchers evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across HIV-1 clades.

Heavily treatment-experienced (HTE) people with human immunodeficiency virus (HIV) (PWH) may not achieve virologic suppression (VS) with combination antiretroviral therapy due to multidrug resistance (MDR), intolerance, and safety concerns. These PWH often receive highly individualized treatment regimens, but these regimens may not enable PWH to achieve VS, thereby halting disease progression. Novel medications are required

The aim of this study was to summarize current evidence regarding lenacapavir, a first in class HIV-1 capsid inhibitor, and its role as an emergent therapy for the treatment of HIV-1 infection.

Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes use of a unique mechanism, can be administered orally or subcutaneously. We sought to explore the efficacy of lenacapavir in various combination regimens as initial and maintenance therapy for HIV.